Myriad Genetics Share Price (NASDAQ: MYGN)

$6.37

▲

0.15

(2.41%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Myriad Genetics Stock chart to analyse performance

Myriad Genetics stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$6.24
Today's High:$6.55
$6.37
2.04%
Downside
Day's Volatility :4.66%
Upside
2.67%
52 Weeks Low:$3.76
52 Weeks High:$29.30
$6.37
40.97%
Downside
52 Weeks Volatility :87.17%
Upside
78.26%

Myriad Genetics Stock Returns

Period	Myriad Genetics Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	30.53%	3.5%	0.0%
6 Months	-38.87%	-7.7%	0.0%
1 Year	-76.8%	-12.6%	0.0%
3 Years	-70.16%	10.0%	-2.3%

Myriad Genetics Inc. Key Stats

Check Myriad Genetics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$6.22
Open	$6.24
Today's High	$6.545
Today's Low	$6.24
Market Capitalization	$592.7M
Today's Volume	$2.6M
52 Week High	$29.3
52 Week Low	$3.76
Revenue TTM	$832.9M
EBITDA	$-17.8M
Earnings Per Share (EPS)	$-4.31
Profit Margin	-47.45%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-70.03%

Stock Returns calculator for Myriad Genetics Stock including INR - Dollar returns

The Myriad Genetics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Myriad Genetics investment value today

Current value as on today

₹28,222

Returns

₹71,778

(-71.78%)

Returns from Myriad Genetics Stock

₹76,803 (-76.8%)

Dollar Returns*

₹5,025 (+5.03%)

Indian investors sentiment towards Myriad Genetics Stock

215.0%

Period: Aug 2, 2025 to Sep 1, 2025. Change in 30 Days versus previous period

Investment in Myriad Genetics Shares from India has grown by 215.0% over the past 30 days, indicating increased transactional activity.

1720%

Period: Aug 2, 2025 to Sep 1, 2025. Change in 30 Days versus previous period

Search interest for Myriad Genetics Stock from India on INDmoney has increased by 1720% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Myriad Genetics Inc.

Name
Holdings %
Name
Holdings %
BlackRock Inc
16.60%
Vanguard Group Inc
9.94%
State Street Corp
5.66%
Glenview Capital Management LLC
4.93%
D. E. Shaw & Co LP
4.85%
Millennium Management LLC
4.37%

Analyst Recommendation on Myriad Genetics Stock

Rating

Trend

Buy

50%Buy

33%Hold

16%Sell

Based on 18 Wall street analysts offering stock ratings for Myriad Genetics(by analysts ranked 0 to 5 stars)

Myriad Genetics Share Price Target

What analysts predicted

Upside of 15.78%

Target:

$7.38

Current:

$6.37

Myriad Genetics share price target is $7.38, a slight Upside of 15.78% compared to current price of $6.37 as per analysts' prediction.

Myriad Genetics Stock Insights

Price Movement
In the last 7 days, MYGN stock has moved up by 9.6%
Increasing Revenue
Revenue is up for the last 2 quarters, 195.9M → 213.1M (in $), with an average increase of 8.1% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -100.0K → -330.5M (in $), with an average decrease of 330400.0% per quarter
MYGN vs IDXX (1 yr)
In the last 1 year, Idexx Laboratories, Inc. has given 34.4% return, outperforming this stock by 111.9%
MYGN vs IDXX (3 yr)
In the last 3 years, Idexx Laboratories, Inc. has given 88.2% return, outperforming this stock by 159.0%
Price to Sales
ForMYGN every $1 of sales, investors are willing to pay $0.7, whereas for Idexx Laboratories, Inc., the investors are paying $13.0 for every $1 of sales.

Myriad Genetics Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY21

FY22

FY23

FY24

	FY21	Y/Y Change
Revenue	$690.6M	↑ 23.99%
Net Income	$-27.2M	↓ 87.84%
Net Profit Margin	-3.94%	↑ 36.22%

	FY22	Y/Y Change
Revenue	$678.4M	↓ 1.77%
Net Income	$-112.0M	↑ 311.76%
Net Profit Margin	-16.51%	↓ 12.57%

	FY22	Y/Y Change
Revenue	$678.4M	↓ 1.77%
Net Income	$-112.0M	↑ 311.76%
Net Profit Margin	-16.51%	↓ 12.57%

	FY23	Y/Y Change
Revenue	$753.2M	↑ 11.03%
Net Income	$-263.3M	↑ 135.09%
Net Profit Margin	-34.96%	↓ 18.45%

	FY23	Y/Y Change
Revenue	$753.2M	↑ 11.03%
Net Income	$-263.3M	↑ 135.09%
Net Profit Margin	-34.96%	↓ 18.45%

	FY24	Y/Y Change
Revenue	$837.6M	↑ 11.21%
Net Income	$-127.3M	↓ 51.65%
Net Profit Margin	-15.2%	↑ 19.76%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$202.2M	↑ 2.85%
Net Income	$-26.0M	↓ 16.67%
Net Profit Margin	-12.86%	↑ 3.01%

	Q2 FY24	Q/Q Change
Revenue	$211.5M	↑ 4.6%
Net Income	$-36.7M	↑ 41.15%
Net Profit Margin	-17.35%	↓ 4.49%

	Q3 FY24	Q/Q Change
Revenue	$213.3M	↑ 0.85%
Net Income	$-22.1M	↓ 39.78%
Net Profit Margin	-10.36%	↑ 6.99%

	Q4 FY24	Q/Q Change
Revenue	$210.6M	↓ 1.27%
Net Income	$-42.5M	↑ 92.31%
Net Profit Margin	-20.18%	↓ 9.82%

	Q1 FY25	Q/Q Change
Revenue	$195.9M	↓ 6.98%
Net Income	$-100.0K	↓ 99.76%
Net Profit Margin	-0.05%	↑ 20.13%

	Q2 FY25	Q/Q Change
Revenue	$213.1M	↑ 8.78%
Net Income	$-330.5M	↑ 330400.0%
Net Profit Margin	-155.09%	↓ 155.04%

FY21

FY22

FY23

FY24

	FY21	Y/Y Change
Profit	$493.0M	-

	FY22	Y/Y Change
Profit	$476.4M	-

	FY23	Y/Y Change
Profit	$517.0M	-

	FY24	Y/Y Change
Profit	$585.4M	↑ 13.23%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$137.6M	↑ 1.93%

	Q2 FY24	Q/Q Change
Profit	$147.1M	↑ 6.9%

	Q3 FY24	Q/Q Change
Profit	$149.8M	↑ 1.84%

	Q4 FY24	Q/Q Change
Profit	$150.9M	↑ 0.73%

	Q1 FY25	Q/Q Change
Profit	$134.2M	↓ 11.07%

	Q2 FY25	Q/Q Change
Profit	$151.8M	↑ 13.11%

FY21

FY22

FY23

FY24

	FY21	Y/Y Change
Operating Cash Flow	$18.6M	↓ 169.14%
Investing Cash Flow	$274.4M	↑ 390.0%
Financing Cash Flow	$-150.6M	↑ 14960.0%

	FY22	Y/Y Change
Operating Cash Flow	$-106.3M	↓ 684.07%
Investing Cash Flow	$-77.5M	↓ 128.24%
Financing Cash Flow	$-8.0M	↓ 94.69%

	FY22	Y/Y Change
Operating Cash Flow	$-106.3M	↓ 684.07%
Investing Cash Flow	$-77.5M	↓ 128.24%
Financing Cash Flow	$-8.0M	↓ 94.69%

	FY23	Y/Y Change
Operating Cash Flow	$-110.9M	↑ 4.33%
Investing Cash Flow	$31.9M	↓ 141.16%
Financing Cash Flow	$152.9M	↓ 2011.25%

	FY23	Y/Y Change
Operating Cash Flow	$-110.9M	↑ 4.33%
Investing Cash Flow	$31.9M	↓ 141.16%
Financing Cash Flow	$152.9M	↓ 2011.25%

	FY24	Y/Y Change
Operating Cash Flow	$-8.7M	↓ 92.16%
Investing Cash Flow	$-11.9M	↓ 137.3%
Financing Cash Flow	$-7.4M	↓ 104.84%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-18.6M	↓ 66.0%
Investing Cash Flow	$-7.1M	↓ 40.83%
Financing Cash Flow	$-8.8M	↓ 107.22%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$2.6M	↓ 113.98%
Investing Cash Flow	$-6.4M	↓ 9.86%
Financing Cash Flow	$2.4M	↓ 127.27%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$700.0K	↓ 73.08%
Investing Cash Flow	$7.5M	↓ 217.19%
Financing Cash Flow	$-3.1M	↓ 229.17%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$6.6M	↑ 842.86%
Investing Cash Flow	$-5.9M	↓ 178.67%
Financing Cash Flow	$2.1M	↓ 167.74%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-16.3M	↓ 346.97%
Investing Cash Flow	$-8.3M	↑ 40.68%
Financing Cash Flow	$13.6M	↑ 547.62%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-13.6M	↓ 16.56%
Investing Cash Flow	$-6.9M	↓ 16.87%
Financing Cash Flow	$2.6M	↓ 80.88%

Myriad Genetics Technicals Summary

Sell

Neutral

Buy

Myriad Genetics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Myriad Genetics Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Myriad Genetics Inc.	60.05%	-38.87%	-76.8%	-70.16%	-48.92%
Agilent Technologies Inc.	9.42%	2.11%	-9.57%	-2.82%	26.11%
Idexx Laboratories, Inc.	-5.23%	46.53%	37.97%	89.36%	69.72%
Thermo Fisher Scientific, Inc.	5.6%	-4.62%	-18.75%	-9.62%	17.41%
Danaher Corp.	4.23%	-0.04%	-22.11%	-24.46%	2.44%
Iqvia Holdings Inc.	4.41%	3.94%	-23.31%	-8.99%	15.78%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Myriad Genetics Inc.	NA	NA	1.4	0.01	-0.7	-0.05	NA	4.17
Agilent Technologies Inc.	29.29	29.29	1.96	5.57	0.2	0.08	0.01	22.46
Idexx Laboratories, Inc.	53.75	53.75	4.84	12.6	0.65	0.23	NA	18.2
Thermo Fisher Scientific, Inc.	28.5	28.5	2.01	22.5	0.13	0.05	0.0	133.77
Danaher Corp.	43.7	43.7	2.06	7.77	0.07	0.04	0.01	73.1
Iqvia Holdings Inc.	27.61	27.61	1.09	11.87	0.2	0.05	NA	33.99

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Myriad Genetics Inc.	Buy	$592.7M	-48.92%	NA	-47.45%
Agilent Technologies Inc.	Buy	$35.7B	26.11%	29.29	17.97%
Idexx Laboratories, Inc.	Buy	$51.8B	69.72%	53.75	24.41%
Thermo Fisher Scientific, Inc.	Buy	$186.1B	17.41%	28.5	15.24%
Danaher Corp.	Buy	$147.4B	2.44%	43.7	14.21%
Iqvia Holdings Inc.	Buy	$32.4B	15.78%	27.61	7.88%

Myriad Genetics Dividend announcements

Myriad Genetics Earnings
Myriad Genetics’s price-to-earnings ratio stands at None

About Myriad Genetics Inc.

Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests in the United States and internationally. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; Memorial Sloan Kettering Cancer Center; the University of Texas MD Anderson Cancer Center; the University of Rochester Medical Center; and Flatiron Health, Inc. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Organization	Myriad Genetics
Employees	2700
CEO	Mr. Samraat S. Raha
Industry	Health Technology

Key Management of Myriad Genetics Inc.

Name	Title
Mr. Samraat S. Raha	President, CEO & Director
Mr. Mark S. Verratti	Chief Operating Officer
Dr. Dale Muzzey Ph.D.	Chief Scientific Officer
Mr. Paul J. Diaz J.D.	Consultant & Director
Mr. Scott J. Leffler	Executive Officer
Mr. Ben Wheeler	Chief Financial Officer
Ms. Natalie Munk	Senior VP & Chief Accounting Officer
Dr. Kevin Richard Haas Ph.D.	Chief Technology Officer
Mr. Matthew Scalo	Senior Vice President of Investor Relations
Ms. Jennifer L. Fox J.D.	Chief Legal Officer

Important FAQs about investing in MYGN Stock from India :

What is Myriad Genetics share price today?

Myriad Genetics share price today is $6.37 as on August 30, 2025 at 1:29 am IST at the close of the market. Myriad Genetics share today touched a day high of $6.55 and a low of $6.24.

What is the 52 week high and 52 week low for Myriad Genetics share?

Myriad Genetics share touched a 52 week high of $29.30 and a 52 week low of $3.76. Myriad Genetics stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $6.37, lower by 78.26% versus the 52 week high.

How to invest in Myriad Genetics Stock (MYGN) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Myriad Genetics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Myriad Genetics Shares that will get you 0.2355 shares as per Myriad Genetics share price of $6.37 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Myriad Genetics Stock (MYGN) from India?

Indian investors can start investing in Myriad Genetics (MYGN) shares with as little as ₹88.1475 or $1 (as of September 02, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹881.47 in Myriad Genetics stock (as per the Rupee-Dollar exchange rate as on September 02, 2025). Based on Myriad Genetics share’s latest price of $6.37 as on August 30, 2025 at 1:29 am IST, you will get 1.5699 shares of Myriad Genetics. Learn more about fractional shares .

What are the returns that Myriad Genetics has given to Indian investors in the last 5 years?

Myriad Genetics stock has given -48.92% share price returns and 20.75% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?